Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. Patients may have received up to 2 prior chemotherapy regimens for small cell lung carcinoma, but no prior therapy with an m-TOR inhibitor. RAD001 will be administered orally at a dose of 10 mg daily. A cycle will be defined as 3 weeks of study drug administration, and patients will have tumor measurements every 2 cycles. Study participation will continue until disease progression or intolerable toxicities. In addition, in patients who consent, archival tumor tissue (paraffin block from original biopsy) will be collected for research purposes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Small Cell Lung Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

small cell lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RAD001 (Everolimus)

RAD001 (Everolimus)10 mg by mouth daily without interruption

Group Type EXPERIMENTAL

RAD001 (everolimus)

Intervention Type DRUG

10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RAD001 (everolimus)

10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Certican®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Cytologically or histologically confirmed small cell carcinoma of the lung that has progressed post first-line therapy. Mixed small and non-small cell tumors are excluded.
2. Prior chemotherapy for small cell carcinoma. Up to 2 prior chemotherapy regimens for small cell lung carcinoma are allowed. No prior therapy with an m-TOR inhibitor (e.g. CCI-779).
3. Unidimensionally measurable disease (RECIST criteria). If the only site of measurable disease is in a previously irradiated area, the patient must have documented progression of disease in this area.
4. ECOG performance status 0-2.
5. A minimum of 4 weeks should elapse from prior chemotherapy. Patients must have fully recovered from the effects of any prior surgery or radiation therapy or other anticancer therapies, including immunotherapy and investigational agents.
6. No progressive brain metastases. Brain metastases should have been previously treated with surgery and/or radiation.
7. Patients with a prior malignancy should have at least 3 years of disease-free survival. Prior curatively treated squamous cell or basal carcinoma of the skin or in situ cervical cancer or other in situ malignancies are allowed.
8. No other coexisting medical condition that would preclude full compliance with the study.
9. Required laboratory values (obtained \< 1 week prior to enrollment):

* ANC \>/= 1500/mm³
* Platelets \>/= 100,000/mm³
* AST and ALT ≤ 3 x ULN (upper limits of normal). In patients with liver metastases AST and ALT should be \< 5 x ULN.
* Total bilirubin up to 1.5 x ULN (upper limits of normal).
10. Age \>/= 18 years and capacity to give informed consent.
11. Patients should be advised to discontinue drugs that interact with CYP3A4 (see list of examples in Table 3.1 of the full protocol), if medically safe.
12. All patients must have given signed, informed consent prior to registration on study.

Exclusion Criteria

1. Prior treatment with any investigational agent within the preceding 4 weeks.
2. Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias active ischemic heart disease, myocardial infarction within six months, chronic liver or renal disease, active upper GI tract ulceration).
3. A known history of HIV seropositivity.
4. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
5. Patients with an active, bleeding diathesis or on anticoagulation (except low dose warfarin).
6. Pregnant and lactating women are excluded from the study because the agents used in this study may be teratogenic to a fetus and there is no information on the excretion of the agents or their metabolites into breast milk.
7. Women of childbearing potential and sexually active males must agree to use an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study.
8. Patients should not be on chronic systemic glucocorticoids or other immunosuppressant.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmad Tarhini

Study Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahmad Tarhini, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UPMC Cancer Center - Teramana Cancer Center - Steubenville

Steubenville, Ohio, United States

Site Status

UPMC Cancer Center - Beaver

Beaver, Pennsylvania, United States

Site Status

UPMC Cancer Center - Clairton

Clairton, Pennsylvania, United States

Site Status

UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg

Greensburg, Pennsylvania, United States

Site Status

UPMC Cancer Center - Oakbrook Commons - Greensburg

Greensburg, Pennsylvania, United States

Site Status

UPMC Cancer Center - Indiana

Indiana, Pennsylvania, United States

Site Status

UPMC Cancer Center - John P. Murtha Pavilion - Johnstown

Johnstown, Pennsylvania, United States

Site Status

UPMC Cancer Center - McKeesport

McKeesport, Pennsylvania, United States

Site Status

UPMC Cancer Center - Monroeville

Monroeville, Pennsylvania, United States

Site Status

UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group

Moon Township, Pennsylvania, United States

Site Status